Optimizing warfarin reversal - An ex vivo study

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 7, 2009, Pages 1123-1127

  Gatt, Alexander ^a,b   Riddell, A ^a   Van Veen, J J ^b   Kitchen, S ^b   Tuddenham, E G ^a   Makris, M ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

INR; PCC; Reversal; Thrombin generation; Warfarin

Indexed keywords

BERIPLEX; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; FRESH FROZEN PLASMA; HEMOSTATIC AGENT; PROTHROMBIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; UNCLASSIFIED DRUG; WARFARIN;

ARTICLE; BLOOD ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; EX VIVO STUDY; HUMAN; HYPERCOAGULABILITY; INTERNATIONAL NORMALIZED RATIO; PRIORITY JOURNAL; THROMBIN TIME;

ANTICOAGULANTS; HUMANS; INTERNATIONAL NORMALIZED RATIO; WARFARIN;

EID: 67649479380     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03435.x     Document Type: Article

References (22)

1. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplex((R)) P/N) for emergency anticoagulation reversal. J Thromb Haemost 2008; 6: 622-31.
2. Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM. Warfarin reversal: Consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004; 181: 492-7.
3. Evans G, Luddington R, Baglin T. Beriplex. P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol 2001; 115: 998-1001.
4. van Aart L, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ, Ploeger B, Strengers PF. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: An open, prospective randomized controlled trial. Thromb Res 2006; 118: 313-20.
5. Makris M. Optimisation of the prothrombin complex concentrate dose for warfarin reversal. Thromb Res 2005; 115: 451-3.
6. Poller L. International Normalized Ratios (INR): The first 20.years. J Thromb Haemost 2004; 2: 849-60.
7. al Dieri R, Alban S, Beguin S, Hemker HC. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost 2004; 2: 1395-401.
8. Gerotziafas GT, Elalamy I, Depasse F, Perzborn E, Samama MM. In.vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor.Xa inhibitor rivaroxaban. J Thromb Haemost 2007; 5: 886-8.
9. Altman R, Scazziota A, Herrera L, Gonzalez C. Relationship between thrombin generation and international normalized ratio in patients receiving oral vitamin.K antagonist therapy. J Thromb Haemost 2007; 5: 1552-69.
10. Jackson CM, Esnouf MP, Lindahl TL. A critical evaluation of the prothrombin time for monitoring oral anticoagulant therapy. Pathophysiol Haemost Thromb 2003; 33: 43-51.
11. Gatt A, van Veen JJ, Bowyer A, Woolley AM, Cooper P, Kitchen S, Makris M. Wide variation in thrombin generation in patients with atrial fibrillation and therapeutic International Normalized Ratio is not due to inflammation. Br J Haematol 2008; 142: 946-52.
12. Gatt A, van Veen JJ, Woolley AM, Kitchen S, Cooper P, Makris M. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost 2008; 100: 350-5.
13. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
14. Tanaka KA, Szlam F, Dickneite G, Levy JH. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. Thromb Res 2008; 122: 117-23.
15. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: The relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77: 477-80.
16. Sarode R, Rawal A, Lee R, Shen YM, Frenkel EP. Poor correlation of supratherapeutic international normalised ratio and vitamin K-dependent procoagulant factor levels during warfarin therapy. Br J Haematol 2006; 132: 604-7.
17. McGlasson DL, Romick BG, Rubal BJ. Comparison of a chromogenic factor.X assay with international normalized ratio for monitoring oral anticoagulation therapy. Blood Coagul Fibrinolysis 2008; 19: 513-17.
18. Hart RG, Aguilar MI. Anticoagulation in atrial fibrillation: Selected controversies including optimal anticoagulation intensity, treatment of intracerebral hemorrhage. J Thromb Thrombolysis 2008; 25: 26-32.
19. Royal Pharmaceutical Society of Great Britain, British Medical Association. BNF, 2002: 55. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2008.
20. Bagot CN Guidelines on oral anticoagulation: Third edition. Br J Haematol 1998; 101: 374-87.
21. Bagot CN, Cregg R, Patel RK, Shariff A, Arya R. Perioperative myocardial infarction in a patient receiving low-dose prothrombin complex concentrates. Thromb Haemost 2007; 98: 1141-2.
22. White R, Rushbrook J, McGoldrick J. The dangers of prothrombin complex concentrate administration after heart surgery. Blood Coagul Fibrinolysis 2008; 19: 609-10.